Reduced plasma mI concentrations have been reported in insulin-resistant states, including obesity and polycystic ovary syndrome, and mI supplementation has been shown to improve insulin sensitivity and metabolic parameters in these conditions [114,115]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.